Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers.
作者信息
Mata Melinda, Gottschalk Stephen
机构信息
Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
出版信息
Mol Ther. 2016 Sep;24(9):1511-2. doi: 10.1038/mt.2016.173.
Abstract
摘要
相似文献
1
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers.人类最好的朋友：利用犬类自然发生的肿瘤改善嵌合抗原受体T细胞疗法治疗人类癌症。
Mol Ther. 2016 Sep;24(9):1511-2. doi: 10.1038/mt.2016.173.
2
WHEN man's best friend is man's worst enemy.当人类最好的朋友成为人类最大的敌人时。
Med Techn Bull. 1953 May-Jun;4(3):113.
3
Man's best friend receives man's best healthcare.人类最好的朋友享受着人类最好的医疗保健。
JONAS Healthc Law Ethics Regul. 2001 Dec;3(4):106-8. doi: 10.1097/00128488-200112000-00004.
4
Man's best friend is also a friend of cancer research.人类最好的朋友也是癌症研究的朋友。
J Natl Cancer Inst. 2008 Jul 16;100(14):984. doi: 10.1093/jnci/djn247. Epub 2008 Jul 8.
5
Dental therapy dogs. Can man's best friend help your practice?牙科治疗犬。人类最好的朋友能对你的诊疗有所帮助吗？
CDS Rev. 2016 Jul;109(4):10-12.
6
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.表达VHH导向的寡克隆嵌合HER2抗原受体的T细胞：迈向肿瘤导向的寡克隆T细胞疗法。
Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27.
7
Man's best friend. Understanding service dogs.人类最好的朋友。了解服务犬。
EMS World. 2012 Sep;41(9):16.
8
Man's best friend.人类最好的朋友。
Nurs Stand. 2003;17(47):17. doi: 10.7748/ns.17.47.17.s30.
9
Man's best friend may be companion in cancer research.人类最好的朋友可能成为癌症研究的伙伴。
J Natl Cancer Inst. 1993 Sep 15;85(18):1455-6. doi: 10.1093/jnci/85.18.1455.
10
Chimeric antigen receptors: driving immunology towards synthetic biology.嵌合抗原受体：推动免疫学迈向合成生物学。
Curr Opin Immunol. 2016 Aug;41:68-76. doi: 10.1016/j.coi.2016.06.004. Epub 2016 Jun 30.
引用本文的文献
1
Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients.未经编辑的同种异体 iNKT 细胞在 MHC 错配的犬受体内具有延长的持久性。
Cell Rep Med. 2023 Oct 17;4(10):101241. doi: 10.1016/j.xcrm.2023.101241.
2
Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.用于检测犬 CD20 嵌合抗原受体转导 T 细胞上抗犬 CD20 嵌合抗原受体表达的单克隆抗体的开发。
J Vet Med Sci. 2021 Oct 2;83(10):1495-1499. doi: 10.1292/jvms.21-0326. Epub 2021 Aug 19.
3
Adoptive cell transfer: new perspective treatment in veterinary oncology.过继性细胞转移：兽医肿瘤学中的新视角治疗方法。
Acta Vet Scand. 2018 Oct 11;60(1):60. doi: 10.1186/s13028-018-0414-4.
本文引用的文献
1
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.RNA转染的CD20特异性嵌合抗原受体T细胞在自发性B细胞淋巴瘤犬中的可行性和安全性
Mol Ther. 2016 Sep;24(9):1602-14. doi: 10.1038/mt.2016.146. Epub 2016 Jul 12.
2
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.为过继性T细胞疗法制备更优的嵌合抗原受体
Clin Cancer Res. 2016 Apr 15;22(8):1875-84. doi: 10.1158/1078-0432.CCR-15-1433.
3
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.用于治疗儿童和青年急性淋巴细胞白血病的表达CD19嵌合抗原受体的T细胞：一项1期剂量递增试验
Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.
4
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
5
Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.在大型动物模型中进行重定向T细胞免疫治疗：犬T细胞的体外激活、扩增和基因改造。
J Immunother. 2014 Oct;37(8):407-15. doi: 10.1097/CJI.0000000000000052.
6
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.犬肿瘤细胞上PD-L1的表达以及通过PD-L1阻断增强肿瘤浸润细胞的IFN-γ产生。
PLoS One. 2014 Jun 10;9(6):e98415. doi: 10.1371/journal.pone.0098415. eCollection 2014.
7
Managing cytokine release syndrome associated with novel T cell-engaging therapies.管理与新型T细胞接合疗法相关的细胞因子释放综合征。
Cancer J. 2014 Mar-Apr;20(2):119-22. doi: 10.1097/PPO.0000000000000035.
8
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
9
Design and development of therapies using chimeric antigen receptor-expressing T cells.嵌合抗原受体表达 T 细胞疗法的设计与开发。
Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131.
10
The basic principles of chimeric antigen receptor design.嵌合抗原受体设计的基本原则。
Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2.
Zotero 插件